恩帕格利弗洛辛在患有慢性心力衰竭的老鼠中改善心脏功能
Zhenzhen Wang1, Qian Liu2, Xiaofang Wang2
1Department of Cardiology, Dongying People's Hospital (Dongying Hospital of Shandong Provincial Hospital Group), No. 317, Dong Cheng Nan Yi Road, Dongying, 257091, Shandong Province, China. Wangzz0925@163.com.
Naunyn-Schmiedeberg's archives of pharmacology
|August 11, 2023
概括
在患有慢性心力衰竭的老鼠中,empagliflozin显著改善了心脏功能. 该药物减少了炎症,氧化应激,改善了心肌纤维化,提供了潜在的治疗机制.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 慢性心力衰竭 (CHF) 是一种复杂的疾病,具有显著的发病率和死亡率.
- 目前治疗心脏不全的治疗方法存在局限性,需要探索新型治疗剂.
- 作为SGLT2抑制剂的empagliflozin在其他疾病中也显示出对心血管的益处,因此需要在心力衰竭模型中进行研究.
研究的目的:
- 在慢性心力衰竭的老鼠模型中研究empagliflozin对心脏功能的影响.
- 阐明Empagliflozin对心脏衰竭产生影响的潜在机制.
主要方法:
- 通过绑定前沿下降冠状动脉,建立了慢性心力衰竭的老鼠模型.
- 鼠被用empagliflozin (30 mg/kg/天) 或盐水治疗了16周.
- 评估了心脏功能,氧化应激标志物 (ROS,MMP),炎症标志物 (hs-CRP,iNOS),NT-proBNP和心肌组织学.
主要成果:
- 与对照组相比,empagliflozin治疗显著改善了心脏功能.
- 恩帕格利弗洛辛降低了细胞内活性氧物种 (ROS) 水平,并增加了线粒体膜潜力 (MMP).
- 血清NT-proBNP和hs-CRP水平显著降低,并且在接受empagliflozin治疗的老鼠中抑制了iNOS表达.
结论:
- 在慢性心力衰竭的老鼠模型中,empagliflozin有效地改善了心脏功能.
- 恩帕格利弗洛辛的治疗益处可能归因于其抗炎和抗氧化特性.
- 恩帕格利弗洛辛通过减轻心肌氧化应激和炎症,显示出作为慢性心力衰竭治疗的潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:26Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364